|
|
|
| Effect of Levothyroxine Tablet and Growth Hormone for Idiopathic Short Children and the Influence on Serum IGF-1 and IGFBP-3 Levels |
| MA Yong, WANG Jifeng, ZHANG Wei |
| Anhui Second People's Hospital, Anhui Hefei 230011, China |
|
|
|
|
Abstract Objective: To study the clinical efficacy of levothyroxine tablets and growth hormone in the treatment of idiopathic short stature in children, and the effects on serum IGF-1 and IGFBP-3 levels. Methods: A total of 110 children with idiopathic short stature admitted to our hospital from June 2014 to July 2018 were enrolled in the study. According to the parity of admission order, they were divided into observation group (odd array) and control group (even array). On the basis of conventional treatment regimen, control group was given recombinant human growth hormone therapy, and observation group was given levothyroxine tablets combined with recombinant human growth hormone, and they were treated for 12 months. The growth effects, thyroid function, levels of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) and incidence rate of adverse reactions were compared between the two groups. Results: The height, weight, bone age and growth rate in the two groups on the 6th and 12th month of treatment were significantly higher than those before treatment (P<0.05), and the growth rate on the 3rd and 12th month of treatment and weight on the 12th month of treatment in observation group were significantly higher than those in control group (P<0.05). The level of thyroid stimulating hormone (TSH) on the 3rd, 6th and 12th month of treatment were significantly decreased in the two groups (P<0.05) while the levels of serum free triiodothyronine (FT3) and serum free thyroxine (FT4) were significantly increased (P<0.05), and the levels in observation group after treatment were significantly different compared with those in control group (P<0.05). The levels of serum IGF-1 and IGFBP-3 on the 3rd, 6th and 12th month of treatment in the two groups were significantly higher than those before treatment (P<0.05), and the level of IGF-1 in observation group was significantly different from that in control group at the same time (P<0.05). During treatment, the incidence rates of adverse reactions in the two groups were 10.91% and 9.09% respectively (P>0.05). Conclusion: Compared with growth hormone alone, levothyroxine tablets combined with growth hormone for idiopathic short stature in children has achieved better clinical results, and to some extent, it improves the growth effects, promotes thyroid function, and increases levels of serum IGF-1 and IGFBP-3.
|
|
|
|
|
|
[1] 任翼,陈江,谭志团,等.重组人生长激素治疗特发性矮小症和生长激素缺乏症的比较[J].广东医学,2016,37(19):2961~2963.
[2] 刘建平,黄路圣,叶林华.胰岛素样生长因子-1水平监测在重组人生长激素治疗特发性矮小症中的临床意义[J].现代中西医结合杂志,2017,26(32):3568~3571.
[3] 陈立黎,朱高慧,熊丰,等.重组人生长激素治疗儿童特发性矮小症远期疗效分析[J].儿科药学杂志,2018,24(6):17~20.
[4] 陈伟伟,刘焕欣,刘晶,等.儿童身材矮小的病因分析及遗传学诊断[J].中国当代儿科杂志,2019,21(4):381~386.
[5] 王斐,朱志颖,刘庆旭,等.生长激素治疗特发性矮小症前后骨转换指标变化的意义[J].中华实用儿科临床杂志,2016,31(20):1541~1545.
[6] 王平,蒋键波,杜姗,等.特发性矮小症患儿血清生长素、瘦素、胰岛素样生长因子、胰岛素样生长因子结合蛋白表达水平及意义[J].中华内分泌外科杂志,2016,10(10):165.
[7] 胡旭昀,桂宝恒,李红豆,等.临床级致病基因的审核归档策略及其在下一代测序研究矮小症遗传病因中的应用实例[J].中华检验医学杂志,2017,40(7):500~504.
[8] 张炫炜,张满燕,沈红,等.重组人生长激素对特发性矮小儿童生长速度和糖脂代谢、骨代谢水平的影响[J].中国医师进修杂志,2018,41(10):887~891. |
|
|
|
2020, Vol. 26 
